Spectrum Pharmaceuticals Receives Complete Response Letter from FDA for Qapzola

On November 17, 2016, Spectrum Pharmaceuticals, Inc. (the “Company”) received a Complete Response Letter from the U.S. Food and Drug Administration (the “FDA”) with respect to the Company’s New Drug Application for Qapzola (apaziquone for...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news